Tenax Therapeutics is a biotechnology business based in the US. Tenax Therapeutics shares (TENX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.05 – an increase of 2.69% over the previous week. Tenax Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.05 |
|---|---|
| 52-week range | $2.77 - $7.89 |
| 50-day moving average | $5.88 |
| 200-day moving average | $5.24 |
| Wall St. target price | $18.85 |
| PE ratio | 3.5621 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.15 from 2025-05-22
| 1 week (2025-05-16) | 4.41% |
|---|---|
| 1 month (2025-04-25) | 6.03% |
| 3 months (2025-02-25) | 4.24% |
| 6 months (2024-11-25) | 21.54% |
| 1 year (2024-05-24) | 75.21% |
|---|---|
| 2 years (2023-05-24) | -77.05% |
| 3 years (2022-05-24) | 941.76 |
| 5 years (2020-05-22) | 1888 |
Valuing Tenax Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tenax Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tenax Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Tenax Therapeutics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -26.6% |
| Return on equity TTM | -39.78% |
| Profit margin | 0% |
| Book value | $27.53 |
| Market Capitalization | $25 million |
TTM: trailing 12 months
We're not expecting Tenax Therapeutics to pay a dividend over the next 12 months.
Tenax Therapeutics's shares were split on a 1:80 basis on 2 January 2024 . So if you had owned 80 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tenax Therapeutics shares – just the quantity. However, indirectly, the new 7900% higher share price could have impacted the market appetite for Tenax Therapeutics shares which in turn could have impacted Tenax Therapeutics's share price.
Over the last 12 months, Tenax Therapeutics's shares have ranged in value from as little as $2.77 up to $7.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tenax Therapeutics's is 1.911. This would suggest that Tenax Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Tenax Therapeutics, Inc. , a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
A deep dive into the highlights and limitations of Frec.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.